Agenus reports 48% estimated three-year survival in recurrent ovarian cancer trial of botensilimab plus balstilimab

Bitget2026/10/03 14:50

Agenus reported three-year follow-up results from its Phase 1b C-800-01 ovarian cancer cohort, presented at IGCS 2026 in Montréal. Follow-up indicated durable survival in heavily pretreated recurrent ovarian cancer, including patients with platinum-resistant or refractory disease. Some patients remained alive without ongoing therapy at the latest cut, supporting a potential long-lasting benefit in a subset of responders. Safety profile remained consistent with prior experience, with no new safety signals or treatment-related deaths reported. BOT and BAL remain investigational, with the update aimed at strengthening the case for broader development in hard-to-treat tumors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261003256338) on October 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Updated version 1 – KKR achieves record-high profits as asset sales and management fees surge

路透社•2026/11/09 12:17

BUZZ – US Stock Market Updates: Nvidia, Genmab, Eli Lilly

路透社•2026/11/09 12:16

BUZZ-Sable Offshore shares fall as refinery shutdown hampers crude sales, putting pressure on cash flow

路透社•2026/11/09 12:16

British Pound hits session highs at 1.3420 amid broadbased US Dollar weakness

FXStreet•2026/11/09 12:00